WAT

Waters Corp
D

WAT

291.46
USD
-1.98
(-0.67%)
مغلق
حجم التداول
17,886
الربح لكل سهم
13
العائد الربحي
-
P/E
26
حجم السوق
17,348,902,930
أصول ذات صلة
A
A
0.330
(0.28%)
119.200 USD
AMGN
AMGN
6.28
(2.16%)
296.49 USD
BAX
BAX
-0.275
(-1.12%)
24.175 USD
BDX
BDX
0.920
(0.47%)
195.920 USD
B
BIO
-1.45
(-0.51%)
285.69 USD
BSX
BSX
-0.975
(-0.94%)
103.180 USD
DHR
DHR
0.460
(0.22%)
210.680 USD
DXCM
DXCM
1.000
(1.25%)
80.980 USD
EW
EW
0.060
(0.08%)
78.250 USD
HOLX
HOLX
-0.225
(-0.33%)
67.840 USD
IDXX
IDXX
-3.00
(-0.46%)
650.79 USD
ILMN
ILMN
-0.005
(-0.01%)
100.105 USD
LH
LH
-0.95
(-0.35%)
270.37 USD
MTD
MTD
-1.64
(-0.12%)
1,312.52 USD
المزيد
الأخبار المقالات

العنوان: Waters Corp

القطاع: Healthcare
الصناعة: Diagnostics & Research
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.